(4)治疗时长:考虑到《Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind,placebo-controlled, phase 3 COMFORT-I trial》披露芦可替尼中位暴露时间可达 149周(约 3年),保守假设未来杰克替尼有望达到 2年的暴露时间;
(4)治疗时长:考虑到《Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind,placebo-controlled, phase 3 COMFORT-I trial》披露芦可替尼中位暴露时间可达 149周(约 3年),保守假设未来杰克替尼有望达到 2年的暴露时间;